Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apretude
Pharma
Gilead races toward filings for long-acting PrEP after trial win
In a phase 3 study, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.
Zoey Becker
Sep 12, 2024 11:45am
MSF calls out GSK's ViiV for nondisclosure clauses in contract
Aug 17, 2023 2:54pm
Viatris, Cipla and Aurobindo sign up to make GSK PrEP generics
Mar 30, 2023 2:00am
GSK changes direction with HIV prevention for Black women
Mar 23, 2023 7:45am
ViiV makes room on the sofa to discuss HIV
Nov 23, 2022 12:18pm
GSK's HIV franchise could reach £7B in 2026: analyst
Oct 21, 2022 11:38am
